Health · Pharma & Biotech · 2 hrs ago
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Avacopan, sold as Tavneos, is a complement pathway inhibitor used for ANCA-associated vasculitis, or AAV.
A study in an Italian registry found that the drug appeared strongly effective.
That result adds evidence about how well avacopan may work in people with AAV.
The finding is described as a possible step toward easing concerns about the drug’s effectiveness.
It does not, by itself, show that those concerns are settled.
No further details about the study or next steps are provided.
An Italian registry study found that avacopan appeared strongly effective for antineutrophil cytoplasmic antibody-associated vasculitis.
Avacopan, also known as Tavneos, is a complement pathway inhibitor.
The study was described as a possible step toward addressing concerns about avacopan’s efficacy.
- Who
- Researchers conducted an Italian registry study of avacopan.
- What
- The study found that avacopan appeared strongly effective for antineutrophil cytoplasmic antibody-associated vasculitis.
- When
- Not stated
- Where
- Italy
- Why
- The study examined avacopan’s efficacy. The article described it as a possible step toward addressing concerns about the drug.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Avacopan, also known as Tavneos
- Condition
- Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
- Study
- Italian registry study
- Finding
- Avacopan appeared strongly effective
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Brazil suspends Peptistrong supplement and orders all batches recalled
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
